首页> 外文期刊>Circulation journal >Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy
【24h】

Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy

机译:日本有高心血管风险起始用他汀类药物治疗的日本患者的治疗模式,他汀类药物耐受性和随后的心血管事件

获取原文
           

摘要

Background: This study examined treatment patterns, possible statin intolerance, and incidence of cardiovascular events (CVEs) in 2 cohorts of patients with high cardiovascular risk (i.e., patients with atherosclerotic cardiovascular disease [ASCVD] and patients with diabetes mellitus). Methods?and?Results: A retrospective cohort study examined adults initiating either a statin or ezetimibe from 1 January 2006 to 31 May 2014 in the Japan Medical Data Center database. The first observed statin or ezetimibe prescription defined the index date. Patients had ≥12 months of pre- and post-index date plan enrollment. Two high-risk cohorts, the ASCVD cohort and diabetes cohort, were created based on diagnoses observed during the 12 months’ pre-index date. Treatment patterns, possible statin intolerance, and incidence of CVEs were reported. In the ASCVD cohort (n=5,302), 32.9% discontinued therapy, 7.7% switched to a non-index statin or non-statin lipid-lowering therapy, and 11.2% augmented index therapy in the 12 months’ post-index date; only 0.3% were using high-intensity statins and 10% had possible statin intolerance. Also, 8.1% had any new CVE during the follow-up period. Treatment patterns and incidence of CVEs among the diabetes cohort were similar to those of the ASCVD cohort. Conclusions: High cardiovascular risk Japanese patients had frequent treatment modifications, although use of high-intensity statin doses was rare. These patterns may indicate that alternative therapies for lipid lowering are needed.
机译:背景:这项研究检查了2个具有高心血管风险的患者(即患有动脉粥样硬化性心血管疾病[ASCVD]的患者和患有糖尿病的患者)的治疗模式,可能的他汀类药物耐受性以及心血管事件(CVE)的发生率。方法和结果:一项回顾性队列研究对日本医学数据中心数据库中从2006年1月1日至2014年5月31日开始使用他汀类药物或依泽替米贝的成年人进行了研究。观察到的第一个他汀类药物或依泽替米贝处方定义了索引日期。患者进行索引前和索引后计划≥12个月。根据在索引前12个月内观察到的诊断,创建了两个高风险队列,即ASCVD队列和糖尿病队列。据报道治疗方式,他汀类药物可能不耐受和CVE发生率。在ASCVD队列中(n = 5,302),在索引后的12个月中,有32.9%的患者终止治疗,有7.7%的患者改用非他汀类或非他汀类降脂治疗,而11.2%的增强指数治疗是在索引后的12个月中。只有0.3%的人使用高强度他汀类药物,而10%的人可能对他汀类药物不耐受。此外,在随访期间有8.1%的患者有新的CVE。糖尿病人群中CVE的治疗方式和发生率与ASCVD人群相似。结论:尽管高剂量他汀类药物的使用很少,但高心血管风险的日本患者经常进行治疗调整。这些模式可能表明需要降低血脂的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号